Pegavision Corp. (6491) AI Stock Analysis

Pegavision Corp.

(TWSE:6491)

Select Model

Rating:76Outperform

Price Target:TWD 444.00▲(13.12% Upside)

Action:initiatedcoverage

Date:11/10/26

Strong profitability and very low leverage are the primary strengths, while weakening operating and free cash flow is the main financial risk. Reasonable valuation supports the score, but mixed-to-weak technical momentum limits the overall result.

Positive Factors

Strong ProfitabilityHigh gross, operating, and net margins indicate that Pegavision converts revenue into substantial earnings and retains meaningful economics in its core eye-care products. This profitability provides internal funding capacity and a durable cushion against moderate cost or mix pressure.

Negative Factors

Weak Cash ConversionOperating cash flow materially below reported net income reduces confidence that accounting profits are translating efficiently into cash. This can constrain internally funded investment and may reflect working-capital needs or timing effects that remain relevant to earnings quality.

Pegavision Corp. (6491) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 29.99B
Dividend Yield: 2.50%
Average Volume (3M): 398.65K
Price to Earnings (P/E): 15.3
Beta (1Y): 0.51
Revenue Growth: 18.45%
EPS Growth: 24.17%
Country: TW
Employees: 9,425
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Pegavision Corp. Business Overview & Revenue Model

Company Description

Pegavision Corporation manufactures and sells medical devices, and optical and precision instruments in Taiwan. It offers soft contact lenses. The company was founded in 2009 and is based in Taoyuan City, Taiwan. Pegavision Corporation is a subsidiar...

Pegavision Corp. Financial Statement Overview

Summary

Strong profitability and an exceptionally conservative balance sheet support the score. Income statement score was 88 and balance sheet score was 93, but cash-flow deterioration, including a 63.7% decline in free cash flow and weaker cash conversion, reduced the composite score.

Income Statement

88Very Positive

Balance Sheet

93Very Positive

Cash Flow

62Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.18B	7.04B	6.82B	6.79B	6.32B	5.60B
Gross Profit	4.18B	3.55B	3.82B	3.67B	3.32B	2.96B
EBITDA	3.22B	2.85B	2.92B	2.96B	2.77B	2.11B
Net Income	1.99B	1.63B	1.83B	1.66B	1.54B	1.25B
Balance Sheet
Total Assets	16.86B	16.17B	14.55B	13.86B	9.56B	8.56B
Cash, Cash Equivalents and Short-Term Investments	3.77B	4.48B	4.26B	6.23B	2.51B	1.92B
Total Debt	1.14B	1.15B	1.01B	1.55B	1.02B	750.68M
Total Liabilities	4.23B	4.44B	3.49B	3.88B	3.08B	3.06B
Stockholders Equity	12.41B	11.63B	10.97B	9.91B	6.43B	5.49B
Cash Flow
Free Cash Flow	417.19M	1.14B	747.33M	-484.77M	618.02M	780.27M
Operating Cash Flow	2.29B	2.61B	4.20B	799.48M	2.05B	2.63B
Investing Cash Flow	-719.27M	-2.15B	-2.48B	-3.40B	-1.43B	-1.85B
Financing Cash Flow	-1.13B	-766.36M	-1.23B	2.27B	-623.26M	-172.25M

Pegavision Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6491 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6491	76Outperform	TWD 31.20B	15.33	―	2.50%	18.45%	24.17%
TW:3019	71Outperform	TWD 36.44B	18.63	―	3.52%	12.69%	3.09%
TW:6176	60Neutral	TWD 26.93B	9.43	―	10.01%	-11.20%	-42.48%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:2426	52Neutral	TWD 24.74B	129.00	―	0.12%	5.26%	―
TW:4743	42Neutral	TWD 22.59B	-101.39	―	―	14.79%	84.54%

* General Sector Average

Performance Comparison

TW:6491 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6491	Pegavision Corp.	392.50	66.34	20.34%
TW:2426	Tyntek Corporation	82.40	66.47	417.26%
TW:3019	Asia Optical Co., Inc.	133.50	-3.85	-2.81%
TW:4743	Oneness Biotech Co., Ltd.	46.25	-16.55	-26.35%
TW:6176	Radiant Opto-Electronics Corp.	80.70	-79.28	-49.56%
TW:7686	A-Top Health Biotech Co., Ltd.	729.00	209.00	40.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Pegavision Corp. AI Stock Analysis